1. Vendor Update
SLA P&HT Division Meeting
April 8, 2008

2. Adis R&D Insight - Statistics
Total number of RDI drug profiles = 23,296
Number of new profiles added per month = 80
Number of significant updates per month = 992
Active drug profiles = 43.1% of the total database.
Inactive/discontinued drug profiles = 56.9% of database.
Number of profiles with chemical structures = 8952
Number of companies covered = 3589
Number of company profiles linked = 406
Number of companies tracked by Lehman Bros =
Number of profiles with a Lehman table = 995
Therapeutic Area Coverage = ALL plus Diagnostic agents, Cell therapies, Gene therapies and Vaccines.
Number of Indications = *February 2008

3. Adis R&D Insight: Sources
Detailed drug profiles derived from the following sources
Company contacts
Press releases
International conferences
Company websites
More than 1,300 biomedical / medical journals

4. Adis R&D Insight NEW! For 2007/2008
Upgraded search functionality
Improved ease of use
Links to original sources
Major improvements to customizing preferences and push alerting
Two enhancements in last 12 months. Q laid groundwork for 2008 improvements.

5. Upgraded Search Functionality
Biological and Chemical Class
BROWSE function
Separate lists for Biological and Chemical classes
List View/Tree View option
Allows searching on synonyms

6. Upgraded Search Functionality
Route and Formulation
New tab allows search by
Route of administration
Formulation

7. Upgraded Search Functionality
Organization
Renamed parameter for better classification of drug developers
Search by Organization Type or Ownership Type

8. Upgraded Search Functionality
Phase
‘Highest Phase’ and ‘Phase is’
New ‘Phase filter’ option
Updated and expanded Phase list

9. Upgraded Search Functionality
Country Hierarchy
Country searching is expanded to provide the ability to confidently and simply search by broad geographical / political region.
Addition of ‘Tree View’

10. Upgraded Search Functionality
Fast Track
Allows to search compounds that were assigned Fast Track status by the FDA in the US

11. Upgraded Search Functionality
‘Orphan Drug’
Orphan Drug designation for a particular indication
Orphan designation country
‘Any Indication or Country’: search ALL profiles were Orphan Drug exists

12. Upgraded Search Functionality
Full Text
‘Full Text’ has replaced the ‘Text Contains’ free text searching option.
Can be partnered with a Category, which will search a specific part of the profile.
Search term will be highlighted in yellow when you open the profile

13. Improved Ease of Use Addition of Disease Qualifiers
a qualifier may be added to an indication
a qualifier comment can be added to provide additional information

14. Improved Ease of Use More Tabular Content
Route listed in Phase of Development Table
Orphan Designation
Brand Name Table

15. Links to Original Sources
Journal FullText option in records
Open access linking capability to link to your journal holdings

16. Customization
Results Page
Choose Columns for viewing on Results Page

17. Customization
Development table
Filtering by search
Sorting by heading

18. Alerts New ALERTS features:
Multiple addresses can be set up for a single alert
Searches from both R&D Insight and Clinical Trials Insight can be included in a single alert
Users will be able to export, print, chart results from their Alerts
Run search from last alert

19. Customer Engagement Activities- 2007
Online Surveys conducted
Key Takeaways
Areas of expanding importance are drug targets and new formulations
Greater need for financial data, patent, and licensing/deals opportunities
Improved ability in accessing specific data points
Timeliness and comprehensiveness is critical

20. Next Steps for Adis R&D Insight
Customer roundtables to determine and continue to drive specific major enhancements
US and Europe during the weeks of March 31st and April 4th
Representation from all user and customer types
Improve comprehensiveness of coverage through the content acquisition initiative (technology and process review)

21. Adis Business Intelligence
Feedback and Comments
Adis Business Intelligence
Client Services
option 1